Table 2.
Tumor response and primary resistance according to of Shh, Wnt1, Wnt2, Wnt3 plasma concentrations at ICI introduction and at the first tumor evaluation.
| Tumor Response | Primary Resistance | ||||||
|---|---|---|---|---|---|---|---|
| Responders (pg/mL) |
Non-Responders (pg/mL) | p | Yes (pg/mL) |
No (pg/mL) |
p | ||
| Shh | Introduction | 365.5 (IQR 282.3–507.6) |
286.4 (IQR 142.2–434.6) |
0.11 | 274.8 (IQR 139.6–372.1) |
386.0 (IQR 212.9–532.5) |
0.03 |
| First evaluation | 467.4 (IQR 282.6–693.2) |
268.2 (IQR 142.3–461.3) |
0.01 | 242.2 (IQR 147.4–304.5) |
454.7 (IQR 236.1–640.2) |
0.009 | |
| Wnt1 | Introduction | 444.5 (IQR 290.6–727.4) |
396.1 (IQR 282.0–668.4) |
0.62 | 557.1 (IQR 296.3–707.1) |
397,3 (IQR 260.4–560.3) |
0.23 |
| First evaluation | 503.3 (IQR 367.8–688.6) |
346.6 (IQR 261.9–567.5) |
0.07 | 371.4 (IQR 266.3–540.8) |
424.4 (IQR 330.0–681.3) |
0.30 | |
| Wnt2 | Introduction | 689.2 (IQR 446.0–1201.5) |
918.6 (IQR 508.0–2138.4) |
0.09 | 1551.4 (IQR 513.8–2381.2) |
778.1 (IQR 502.2–1410.9) |
0.10 |
| First evaluation | 937.8 (IQR 469.4–1098.7) |
835.2 (IQR 563.3–1530.5) |
0.71 | 831.2 (IQR 534.1–1773.3) |
928.6 (IQR 482.4–1131.8) |
0.90 | |
| Wnt3 | Introduction | 270.4 (IQR 95.7–382.8) |
331.6 (IQR 244.6–409.7) |
0.20 | 320.6 (IQR 234.7–487.1) |
318.7 (IQR155.4–386.5) |
0.67 |
| First evaluation | 358.8 (IQR 189.5–398.0) |
319.2 (IQR 59.5–474.0) |
0.78 | 335.8 (IQR 64.5–441.7) |
354.6 (IQR 140.9–449.4) |
0.63 | |
IQR: Interquartile Range; NR: not reached.